AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook
AbbVie Inc. (NYSE: ABBV) has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and a string of oncology milestones — capped by an HSBC upgrade that just put AbbVie on the firm’s “preferred buys” list for 2026. Barchart.com+224/7 Wall St.+2 At the same time, the stock is still trading below its early‑October high, and investors are weighing Humira’s ongoing decline, softness in aesthetics, and regulatory risk against that growth story. Here’s a detailed look